NCT05740956

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 in Patients With Advanced Solid Tumors

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 318 (estimated)
• Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

Conditions

• Ovarian Cancer
• Breast Cancer
• Pancreatic Cancer
• Prostatic Cancer
• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	HS-10502	HS-10502 will be administered once per day on a continuous dosing schedule starting on Cycle 1 Day 1 (C1D1) in a 28-day treatment cycle.

Timeline

• Start date: 2023-06-09
• Primary completion: 2026-04-01
• Completion: 2026-10-01
• First posted: 2023-02-23
• Last updated: 2025-06-05

Locations

1 site across 1 country: China